Fat-cell-destroying injection CBL-514 cut visceral fat in a small phase 2 MRI analysis

On October 11, 2026, ScienceDaily published a story, based on materials from the European Association for the Study of Diabetes (EASD), about CBL-514, an experimental injection highlighted at the EASD annual meeting in Milan ^[1]. The drug is developed by Caliway Biopharmaceuticals of New Taipei City, Taiwan, and is designed to trigger apoptosis, a natural process of programmed cell death, in adipocytes, the cells that store fat ^[1]. A pooled MRI analysis from two phase 2 trials found that visceral fat fell in treated participants and rose in those given placebo ^[1].

What the human data show

Subcutaneous fat is the layer just beneath the skin, while visceral fat lies deeper, surrounding abdominal organs such as the liver and intestines ^[1]. In phase 2 trials, 69.6% of CBL-514 recipients had lost at least 150 mL of subcutaneous fat volume at the eight-week follow-up, compared with none of the placebo recipients ^[1].

The visceral fat analysis was led by W. Timothy Garvey of the University of Alabama at Birmingham and Yu-Fang Ling of Caliway, using participants from trials CBL-0204 and CBL-0205 who had undergone MRI ^[1]. Adults with a body mass index (BMI) of 22 to 30 kg/m2 received injections into the lower abdomen every three weeks for up to 12 weeks; the number of injections depended on fat thickness, and treatment stopped once thickness fell below a set threshold ^[1]. Of 41 people in the subgroup, 23 were assigned to CBL-514 and 18 to placebo; 40 had data at the later follow-up ^[1].

• Baseline mean visceral fat volume was 563.85 mL in the CBL-514 group and 659.81 mL in the placebo group ^[1].
• Four weeks after the final injection, visceral fat had changed by -12.01% with CBL-514 and +5.68% with placebo, a difference of 17.69 percentage points ^[1].
• At 8 weeks (CBL-0205) or 12 weeks (CBL-0204) after treatment, the changes were -10.45% and +11.76%, a difference of 22.21 percentage points ^[1].

The researchers described the reduction versus placebo as significant, but the story reports no p-values or confidence intervals ^[1]. Most side effects were temporary injection-site pain, swelling and redness, rated mild to moderate, and no serious adverse events were reported ^[1].

The weight-regain question

The story groups Ozempic, Wegovy, Mounjaro and Zepbound as GLP-1 receptor agonist medications and notes that many people regain weight after stopping them ^[1]. In rats, CBL-514 combined with tirzepatide produced more weight loss than tirzepatide alone, and after tirzepatide was stopped, rats that had received both drugs regained less weight ^[1]. The researchers hypothesize that fewer fat cells may slow fat re-accumulation, but the story states that this benefit has so far been shown only in animals and has not been confirmed in humans ^[1].

Why it matters to these readers

For readers considering body-contouring surgery, the researchers note that liposuction and abdominoplasty mainly remove or reshape subcutaneous fat and do not directly address visceral fat ^[1]. The story describes excess visceral fat as a major contributor to insulin resistance, type 2 diabetes and cardiometabolic disease ^[1]. Garvey called CBL-514 "a highly innovative approach to obesity pharmacotherapy" ^[1]. It remains experimental, so decisions about current options belong in a conversation with a clinician ^[1].

What to watch next

Recruitment had begun for the first of two phase 3 trials, both randomized and placebo-controlled, with initial results expected at the end of the following year ^[1]. Those trials are meant to show whether the fat reductions replicate in broader populations and whether fewer fat cells produce lasting weight and metabolic benefits, particularly after people stop GLP-1 medications ^[1].

Limitations

• The visceral fat analysis was small, with 23 CBL-514 and 17 placebo participants at the later follow-up ^[1].
• Enrollment was limited to a BMI of 22 to 30 kg/m2, so the results do not directly describe people with higher BMI ^[1].
• The groups differed at baseline in visceral fat volume and in sex mix, with 74% women in the CBL-514 group and 56% in the placebo group ^[1].
• The reported human outcomes are fat volumes; the story gives no human data on body weight, blood pressure, glucose or cholesterol ^[1].
• Follow-up extended at most 12 weeks after the final injection ^[1].
• The account is a meeting highlight relayed through EASD-provided materials, which ScienceDaily notes may be edited for style and length ^[1].